Skip to content

Study · Non-randomized trial · 1995

5 results

Glucagon impact immunity of the patients with cirrhosis

Wang Yi, Wang Xin, Xu Caifu, Zhao Guoning, Huang Yuxin

Journal of the Fourth Military Medical University1 Jan 1995

PepBankPUB-92344154
Ask about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse.

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, glucagon reduced serum immunoglobulin, with a significant IgG effect (P<0.05), but the result-specific comparator was not stated.

    In plain wordsIn patients with cirrhosis, glucagon reduced immunoglobulin. The abstract does not specify whether the IgG comparison used insulin or pretreatment values.

    Peptide
    Glucagon
    Outcome
    DecreaseSerum immunoglobulin (SIg), with significant effect on IgG
    Study

    n: not reported in source

    Comparator
    Insulin treatment and pretreatment values; result-specific comparator not stated
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    The results showed that glucagon can modulate the immunity of patients with cirrhosis: decrease SIg, increase T cell number, regulate T cell subset, improve macrophage phagocytosis, specially to IgG (P<0.05), CD+8(P<0.01), CD+4/CD+8(P<0.05) and macrophage phagocytic rate (P<0.05) has significant effect.
    1 context sentence
    Summary · context
    We detected Serum immunoglobulin (SIg), T cell subset and macrophage phagocytosis respectively in 35 patients were with posthepatits B cirrhosis. Among them, 32 cases were determined again after glucagon or insulin treatment for 2 weeks. Twelve cases of glucagon-treatment compared with 20 cases trea…
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, glucagon significantly affected CD+8 (P<0.01), but the direction and result-specific comparator were not stated.

    In plain wordsIn patients with cirrhosis, glucagon affected CD+8. The abstract does not specify whether this comparison used insulin or pretreatment values.

    Peptide
    Glucagon
    Outcome
    Direction not reportedCD+8
    Study

    n: not reported in source

    Comparator
    Insulin treatment and pretreatment values; result-specific comparator not stated
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    The results showed that glucagon can modulate the immunity of patients with cirrhosis: decrease SIg, increase T cell number, regulate T cell subset, improve macrophage phagocytosis, specially to IgG (P<0.05), CD+8(P<0.01), CD+4/CD+8(P<0.05) and macrophage phagocytic rate (P<0.05) has significant effect.
    1 context sentence
    Summary · context
    We detected Serum immunoglobulin (SIg), T cell subset and macrophage phagocytosis respectively in 35 patients were with posthepatits B cirrhosis. Among them, 32 cases were determined again after glucagon or insulin treatment for 2 weeks. Twelve cases of glucagon-treatment compared with 20 cases trea…
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, glucagon significantly affected the CD+4/CD+8 ratio (P<0.05), but the direction and result-specific comparator were not stated.

    In plain wordsIn patients with cirrhosis, glucagon affected the CD+4/CD+8 ratio. The abstract does not specify whether this comparison used insulin or pretreatment values.

    Peptide
    Glucagon
    Outcome
    Direction not reportedCD+4/CD+8 ratio
    Study

    n: not reported in source

    Comparator
    Insulin treatment and pretreatment values; result-specific comparator not stated
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    The results showed that glucagon can modulate the immunity of patients with cirrhosis: decrease SIg, increase T cell number, regulate T cell subset, improve macrophage phagocytosis, specially to IgG (P<0.05), CD+8(P<0.01), CD+4/CD+8(P<0.05) and macrophage phagocytic rate (P<0.05) has significant effect.
    1 context sentence
    Summary · context
    We detected Serum immunoglobulin (SIg), T cell subset and macrophage phagocytosis respectively in 35 patients were with posthepatits B cirrhosis. Among them, 32 cases were determined again after glucagon or insulin treatment for 2 weeks. Twelve cases of glucagon-treatment compared with 20 cases trea…
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, glucagon improved macrophage phagocytic rate (P<0.05), but the result-specific comparator was not stated.

    In plain wordsIn patients with cirrhosis, glucagon improved macrophage phagocytosis. The abstract does not specify whether this comparison used insulin or pretreatment values.

    Peptide
    Glucagon
    Outcome
    IncreaseMacrophage phagocytic rate
    Study

    n: not reported in source

    Comparator
    Insulin treatment and pretreatment values; result-specific comparator not stated
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    The results showed that glucagon can modulate the immunity of patients with cirrhosis: decrease SIg, increase T cell number, regulate T cell subset, improve macrophage phagocytosis, specially to IgG (P<0.05), CD+8(P<0.01), CD+4/CD+8(P<0.05) and macrophage phagocytic rate (P<0.05) has significant effect.
    1 context sentence
    Summary · context
    We detected Serum immunoglobulin (SIg), T cell subset and macrophage phagocytosis respectively in 35 patients were with posthepatits B cirrhosis. Among them, 32 cases were determined again after glucagon or insulin treatment for 2 weeks. Twelve cases of glucagon-treatment compared with 20 cases trea…
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, glucagon increased T cell number, but the result-specific comparator was not stated.

    In plain wordsIn patients with cirrhosis, glucagon increased T cell number. The abstract does not specify whether this comparison used insulin or pretreatment values.

    Peptide
    Glucagon
    Outcome
    IncreaseT cell number
    Study

    n: not reported in source

    Comparator
    Insulin treatment and pretreatment values; result-specific comparator not stated
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    The results showed that glucagon can modulate the immunity of patients with cirrhosis: decrease SIg, increase T cell number, regulate T cell subset, improve macrophage phagocytosis, specially to IgG (P<0.05), CD+8(P<0.01), CD+4/CD+8(P<0.05) and macrophage phagocytic rate (P<0.05) has significant effect.
    1 context sentence
    Summary · context
    We detected Serum immunoglobulin (SIg), T cell subset and macrophage phagocytosis respectively in 35 patients were with posthepatits B cirrhosis. Among them, 32 cases were determined again after glucagon or insulin treatment for 2 weeks. Twelve cases of glucagon-treatment compared with 20 cases trea…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

The source lists no publication types, MeSH terms or keywords.

PepBank is a research reference. Talk to a doctor before you use any peptide.